DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER).
Dextrose provides a source of calories and energy by entering the glycolytic pathway and being metabolized to carbon dioxide and water. Potassium chloride replenishes potassium ions, which are essential for nerve impulse conduction, muscle contraction, and maintaining intracellular osmotic pressure.
| Metabolism | Dextrose is metabolized via glycolysis and the citric acid cycle. Potassium is primarily excreted by the kidneys with a small amount lost in feces. |
| Excretion | Potassium: >90% renal excretion. Dextrose: metabolized to CO2 and water; no significant renal excretion of intact glucose unless hyperglycemia exceeds renal threshold. |
| Half-life | Not applicable as a single drug; potassium's terminal half-life ~12-24 hours (depends on total body stores and renal function); dextrose half-life ~15-20 minutes (highly variable with insulin response). Clinical context: half-life relevant only for potassium monitoring in renal impairment. |
| Protein binding | Dextrose: negligible; Potassium: negligible. |
| Volume of Distribution | Dextrose: Vd ~0.2 L/kg (rapidly distributes in extracellular fluid); Potassium: Vd ~0.5 L/kg (total body water; 98% intracellular, 2% extracellular). |
| Bioavailability | Intravenous: 100%. Not administered orally. |
| Onset of Action | Intravenous: Dextrose: immediate hyperglycemic effect within seconds; Potassium: onset of cardiac effect (ECG changes) within minutes; clinical effect on serum potassium within 30-60 minutes. |
| Duration of Action | Dextrose: 30-60 minutes (blood glucose increase) depending on insulin response; Potassium: duration of infusion-dependent; single dose effect lasts hours; continuous infusion maintains steady state. |
Intravenous infusion of potassium chloride 0.3% in dextrose 5% at a rate determined by potassium deficit and patient tolerance, typically 10-20 mEq per hour; maximum infusion rate 40 mEq/hour in non-emergency situations.
| Dosage form | INJECTABLE |
| Renal impairment | GFR less than 30 mL/min: Avoid use unless documented hypokalemia and serum potassium monitoring; maximum dose 40 mEq/day. GFR 30-60 mL/min: Reduce infusion rate, maximum 40 mEq every 2 hours. GFR greater than 60 mL/min: No adjustment necessary. |
| Liver impairment | No specific adjustment for uncomplicated hepatic disease. In severe hepatic impairment (Child-Pugh C) with ascites, use with caution due to risk of hyperkalemia; monitor serum potassium closely and limit dose to 40 mEq/day. |
| Pediatric use | Intravenous infusion: 0.2-0.5 mEq/kg/hour for maintenance; for hypokalemia, 0.5-1 mEq/kg/dose over 1-2 hours, maximum 40 mEq per dose. Dilute to maximum concentration 80 mEq/L (0.8%) in dextrose solutions. |
| Geriatric use | Reduce initial infusion rate to 50% of adult rate; maximum 20 mEq/hour. Monitor serum potassium and renal function closely due to age-related decline in GFR; avoid use if GFR < 30 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER (DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER).
| Breastfeeding | Dextrose and potassium are normal constituents of human milk. Intravenous administration of this solution in lactating women is unlikely to affect milk composition significantly. No specific M/P ratio available. Use with caution in nursing mothers; consider the need for IV therapy and potential risks to the infant from maternal electrolyte disturbances. |
| Teratogenic Risk | Pregnancy Category C. No well-controlled studies in pregnant women. Dextrose is essential for maternal and fetal energy metabolism; potassium chloride is critical for electrolyte balance. At therapeutic doses, no specific teratogenic effects reported. However, hyperglycemia or hyperkalemia from excessive administration may cause fetal harm, including macrosomia, neonatal hypoglycemia, or cardiac arrhythmias. Use during first trimester only if clearly needed; monitor glucose and potassium levels closely during second and third trimesters. |
■ FDA Black Box Warning
Concentrated potassium solutions should not be infused undiluted; must be diluted and administered via infusion pump to prevent fatal hyperkalemia.
| Serious Effects |
["Hyperkalemia","Presence of hyperkalemia with chronic renal failure","Concomitant use with potassium-sparing diuretics or ACE inhibitors without careful monitoring"]
| Precautions | ["Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hyperkalemia. Monitor serum potassium and glucose levels. Do not administer unless solution is clear and container is undamaged."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum glucose, potassium, and electrolytes periodically during prolonged infusion. Monitor fetal heart rate and uterine activity if used during labor. Assess maternal vital signs and fluid status to prevent volume overload or electrolyte imbalances. In pregnancy, monitor blood glucose more frequently to avoid maternal hyperglycemia. |
| Fertility Effects | No known adverse effects on fertility from dextrose 5% and potassium chloride 0.3% at therapeutic doses. However, underlying conditions requiring this solution (e.g., dehydration, electrolyte imbalances) may affect reproductive function. No human or animal data specifically addressing fertility effects. |